RespireRx Pharmaceuticals Inc (fka RSPI)

[jerrydylan]

A conversation I had with a higher up @ Cortex( MV) went as follows......"_my name_, you can't imagine the difference in the amount of (upfront money) involved with ADHD, when you have phase 2 data." End quote. I am sure given that an ADHD deal was done deal back in 2006-2007, and someone went to Europe alongside Cortex lobbying for CX-717 to re-enter human trials, that the interest in ADHD is still very viable. Everyone here has seen the slide with the CX-1739 animal data basically matching stimulants, so I think ADHD is going to be a big deal-but I am pretty sure Mark and Roger want human data. They don't want a Servier/ Organon deal ever again. I believe SGP's trial was POC oriented-they'd get smoked in the long run by better molecules. So I believe ADHD will re-energize the company in the markets-but we have to get there. I think Shire is very likely to be the eventual winner, because they couldn't ever be the loser-I am also with Neuro that a Hospital-sales based outfit even someone huge like Baxter would be a very good fit for RD. And it would pay off much better than PFE/WYE. (Return on Investment )